AGN Media thread, page-132

That is the dosing for Stroke trial. Was never related to Alzheimers, TBI and other conditions. Until they finish off their studies they will then inform us of the dosing. It has never been stated by the CEO that these dosings will be used in any other condition. So until they begin to move forward with these trials we need to wait and see. We need to save our money for this completion of this current phase 2 trial and further studies as they get more expensive as this moves further down the track. To begin to start multiple studies at once costs more than our current market cap so we are waiting years for TBI, Alzheimers and further conditions. So let’s just get this phase 2 off the ground by end of next year. But once the safety is ticked off by stages share price will be running into next year for sure